Substance
ID:937
Names and Identifiers
Synonyms
Oxybutynin HydrochlorideOxybutininoxybutyninoxybutynin topical gelOxibutinina [INN-Spanish]OxibutyninumOxybutynin BaseOxybutynin ChlorideOxybutyninum [INN-Latin]transdermal patchOxybutyninOxybutynine [INN-French]
Brand Name
DitropanOxytrolDitropan Xl
IUPAC name
4-(diethylamino)but-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate
IUPAC Traditional name
oxybutynin
Properties
Physical Property
Hydrophobicity(logP)
4.3
Molecule Details
Drug Groups
approved; investigational
Description
Oxybutynin is an anticholinergic medication used to relieve urinary and bladder difficulties, including frequent urination and inability to control urination, by decreasing muscle spasms of the bladder. It competitively antagonizes the M1, M2, and M3 subtypes of the muscarinic acetylcholine receptor.
Indication
For the treatment of overactive bladder.
Pharmacology
Oxybutynin is an antispasmodic, anticholinergic agent indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. Oxybutynin relaxes bladder smooth muscle. Oxybutynin exhibits only one-fifth of the anticholinergic activity of atropine on the rabbit detrusor muscle, but four to ten times the antispasmodic activity. Antimuscarinic activity resides predominantly in the R-isomer.
Toxicity
LD50=1220 mg/kg (Orally in rats, Goldenthal)
Affected Organisms
Humans and other mammals
Biotransformation
Hepatic, primarily by CYP3A4
Absorption
Rapidly absorbed from gastrointestinal tract.
Half Life
12.4-13.2 hours
Protein Binding
91%-93%
Elimination
Oxybutynin is metabolized primarily by the cytochrome P450 enzyme systems, particularly CYP3A4, found mostly in the liver and gut wall. Oxybutynin is extensively metabolized by the liver, with less than 0.1% of the administered dose excreted unchanged in the urine.
Also, less than 0.1% of the administered dose is excreted as the metabolite N-desethyloxybutynin.
Also, less than 0.1% of the administered dose is excreted as the metabolite N-desethyloxybutynin.
Distribution
* 193 L
References
•
Tupker RA, Harmsze AM, Deneer VH: Oxybutynin therapy for generalized hyperhidrosis. Arch Dermatol. 2006 Aug;142(8):1065-6.
[Pubmed]
•
Mijnhout GS, Kloosterman H, Simsek S, Strack van Schijndel RJ, Netelenbos JC: Oxybutynin: dry days for patients with hyperhidrosis. Neth J Med. 2006 Oct;64(9):326-8.
[Pubmed]
•
Schollhammer M, Misery L: Treatment of hyperhidrosis with oxybutynin. Arch Dermatol. 2007 Apr;143(4):544-5.
[Pubmed]
External Links
Molecular Spectra
No Data Available
Click here to submit data
References
• Tupker RA, Harmsze AM, Deneer VH: Oxybutynin therapy for generalized hyperhidrosis. Arch Dermatol. 2006 Aug;142(8):1065-6. Pubmed
• Mijnhout GS, Kloosterman H, Simsek S, Strack van Schijndel RJ, Netelenbos JC: Oxybutynin: dry days for patients with hyperhidrosis. Neth J Med. 2006 Oct;64(9):326-8. Pubmed
• Schollhammer M, Misery L: Treatment of hyperhidrosis with oxybutynin. Arch Dermatol. 2007 Apr;143(4):544-5. Pubmed